elhamkhani
/
Test2
/
Login
Register
TriplyDB
Test2
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
1
Q48465476-0FE4BE10-D840-4B5F-AE69-C4F98CA6B565
Q48465476-0FE4BE10-D840-4B5F-AE69-C4F98CA6B565
BestRank
Statement
http://www.wikidata.org/entity/statement/Q48465476-0FE4BE10-D840-4B5F-AE69-C4F98CA6B565
mAb806 binding to epidermal growth factor receptor: a computational study.
P2860
Q48465476-0FE4BE10-D840-4B5F-AE69-C4F98CA6B565
BestRank
Statement
http://www.wikidata.org/entity/statement/Q48465476-0FE4BE10-D840-4B5F-AE69-C4F98CA6B565
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
c6fe543b238b39bc5884afd43189dcc9e8bb83c9
P2860
Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer.